JP Morgan Chase’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

JP Morgan Chase’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-607,049	Closed	-$4.05M	–	7998
2023 Q3	$4.05M	Sell	607,049 -42,943	-7%	-$357K	﹤0.01%	2991
2023 Q2	$5.89M	Buy	649,992 +581,750	+852%	+$5.13M	﹤0.01%	2733
2023 Q1	$496K	Sell	68,242 -57,004	-46%	-$423K	﹤0.01%	4510
2022 Q4	$914K	Buy	125,246 +84,438	+207%	+$627K	﹤0.01%	4111
2022 Q3	$315K	Buy	40,808 +1,032	+3%	+$8.76K	﹤0.01%	4727
2022 Q2	$271K	Buy	39,776 +19,616	+97%	+$150K	﹤0.01%	4912
2022 Q1	$160K	Sell	20,160 -16,227	-45%	-$103K	﹤0.01%	5298
2021 Q4	$204K	Buy	+36,387	New	+$273K	﹤0.01%	5340

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

JP Morgan Chase's PNT Position: Q4 2023 in Review

JP Morgan Chase sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 607,049 shares — an estimated $4.05M sold.

JP Morgan Chase first reported a position in PNT in Q4 2021 and held it in 8 quarters. The position peaked at $5.89M in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

JP Morgan Chase reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
JP Morgan Chase sold 607,049 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $4.05M.
JP Morgan Chase first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 8 quarters.
JP Morgan Chase's POINT Biopharma Global Inc. Common Stock position peaked at $5.89M in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.